Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins as Strategic Adviser to Advance Dendritic Cell Cancer Vaccine Platform
核心洞察
Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins, a distinguished biopharma leader with over 25 years of experience, as Strategic Adviser to advance its DCVax® dendritic cell-based cancer vaccine platform.
The company's lead program DCVax®-L (搜索) for glioblastoma (搜索) has completed a 331-patient Phase III trial and submitted a Marketing Authorization Application to the UK's MHRA for commercial approval.
The DCVax® platform is designed to address solid tumors (搜索), which represent approximately 90% of all cancers, with clinical trials encompassing 16 diverse tumor types.
Northwest Biotherapeutics announced the appointment of Dr. Annalisa Jenkins as Strategic Adviser to support the continued development and expansion of the company's dendritic cell-based cancer vaccine platform. Dr. Jenkins brings over 25 years of biopharma leadership experience, including global R&D executive roles at major pharmaceutical companies, biotech CEO positions, and membership on the U.S. FDA Science Board.
Strategic Leadership Addition
Dr. Jenkins, recently honored with the Order of the British Empire (OBE) for her contributions to life sciences and global health leadership, has an exceptional track record of building and financing biotech companies focused on challenging diseases. She previously served as President and CEO of Dimension Therapeutics (搜索), a gene therapy company that she took public on NASDAQ and subsequently sold to Ultragenyx.
Her extensive pharmaceutical industry experience includes serving as Head of Global Research and Development and Executive Vice President of Global Development and Medical at Merck Serono, and Senior Vice President and Head of Global Medical Affairs at Bristol-Myers Squibb, where she spent 15 years.
"Glioblastoma (搜索) remains one of the most devastating diagnoses in oncology, with survival outcomes that have barely moved in two decades," commented Dr. Jenkins. "I have long believed that personalised, cell-based immunotherapies represent one of the most promising frontiers we have — not just for GBM, but across the full spectrum of solid tumours, which account for the vast majority of cancer deaths worldwide."
DCVax® Platform Development
Northwest Biotherapeutics' lead program is DCVax®-L (搜索) treatment for both newly diagnosed and recurrent glioblastoma (搜索). The company has submitted a Marketing Authorization Application (MAA) to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and is actively engaged in the Agency's review process.
The DCVax®-L (搜索) program has completed a 331-patient Phase III trial for glioblastoma (搜索), with results presented at scientific meetings and published in JAMA Oncology. Glioblastoma is described as the most aggressive and lethal form of primary brain cancer (搜索) and is classified as an orphan disease.
Broad Platform Applications
The DCVax® platform is anticipated to be applicable to most types of solid tumors (搜索), both operable and inoperable. Solid tumors represent approximately 90% of all cancers and present a distinctive therapeutic challenge due to their typical high heterogeneity, unlike blood cancers. The company believes its dendritic cell-based technology is uniquely suited to address this heterogeneity.
To date, the company's clinical trials have included 16 diverse types of solid tumors (搜索), and compassionate use programs have extended to additional indications. The company has also developed DCVax®-Direct (搜索) for inoperable solid tumor cancers, completing a 40-patient Phase I trial with plans to pursue Phase II trials this year.
Clinical Development Pipeline
Northwest Biotherapeutics previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer (搜索) in collaboration with the University of Pennsylvania. The company is working to build a leading franchise in dendritic cell-based cancer vaccines designed to treat cancers more effectively than current treatments, without the toxicities associated with chemotherapies.
"We are very excited to be joining forces with Dr. Jenkins in working to bring urgently needed new treatments to glioblastoma (搜索) patients, for whom there has been virtually no improvement in survival in over 20 years," commented Linda Powers, the company's CEO. "We believe that Dr. Jenkins' extensive expertise, especially in novel technologies, her deep commitment to glioblastoma patients and her experience spanning drug development, regulatory strategy, and commercialization, can be enormously helpful in accelerating these treatments for patients."